Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



The Exubera Winner

The most disastrous, if least surprising, news from Pfizer's (NYSE: PFE  ) third-quarter earnings announcement yesterday was its surrender of the rights to market inhalable-insulin treatment Exubera to developer Nektar Therapeutics (Nasdaq: NKTR  ) . The compound may be a flop commercially, but for one unexpected drugmaker, it's been a bonanza.

Pfizer and Nektar have previously stated that sales of Exubera have been dismal since its FDA approval in January 2006. Yesterday, Pfizer revealed just how dismal. In the first nine months of 2007, the diabetes treatment generated $12 million in sales, with $7 million of that in the most recent quarter. That's a far cry from the $2 billion blockbuster Pfizer predicted Exubera would eventually become, even as recently as this year.

Besides the millions of dollars Pfizer wasted in marketing Exubera, it also paid developer Nektar more than $100 million in just the first two quarters of 2007 to manufacture the drug and further research it.  

It would be easy to dub other inhalable insulin developers, like MannKind (Nasdaq: MNKD  ) , Novo Nordisk (NYSE: NVO  ) or Eli Lilly (NYSE: LLY  ) , the winners here. After all, they've just lost a large pharma rival. But it's still not clear that their compounds won't share the same concerns Exubera raised regarding long-term pulmonary safety or insurer formulary coverage.

No, the one clear winner from this debacle is Sanofi-Aventis (NYSE: SNY  ) , for which Exubera has been a billion-dollar blockbuster. A few weeks before the FDA approved the treatment in early 2006, Sanofi agreed to give up its co-marketing rights to the drug in exchange for $1.3 billion from Pfizer.

In hindsight, it's easy to see that Pfizer overpaid for full marketing rights to the drug. Even more ironically, just last week, Pfizer was rumored as a possible buyer for Sanofi. If the rumors are true, for the sake of Pfizer's investors, let's hope it won't overpay Sanofi twice in two years.

Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 538879, ~/Articles/ArticleHandler.aspx, 10/27/2016 3:16:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
NKTR $12.61 Down -0.17 -1.33%
Nektar Therapeutic… CAPS Rating: ***
PFE $32.40 Up +0.12 +0.37%
Pfizer CAPS Rating: ****
LLY $76.76 Down -0.99 -1.27%
Eli Lilly and Co. CAPS Rating: ***
MNKD $0.51 Down -0.02 -2.97%
MannKind CAPS Rating: *
NVO $40.24 Down -0.09 -0.22%
Novo Nordisk CAPS Rating: *****
SNY $37.06 Down -0.33 -0.88%
Sanofi CAPS Rating: *****